Clovis Oncology, Inc. (CLVS)

Trade CLVS now with
10/11/2018 4:10:29 PM Clovis Oncology Appoints Robert Azelby And Richard Fair To Its Board Of Directors
10/2/2018 8:23:34 AM Clovis Oncology Shares Up 8.72% In Premarket After Breakthrough Designation From FDA For Rubraca
10/2/2018 8:10:13 AM Clovis Oncology Receives Breakthrough Therapy Designation For Rubraca For BRCA1/2-mCRPC
8/8/2018 8:05:11 AM Clovis Oncology Announces First Patient Enrolled In Phase 3 ATHENA Trial
6/4/2018 6:03:58 AM Clovis Oncology Submits Application To EMA To Expand Marketing Authorization For Rubraca
5/29/2018 8:07:27 AM Clovis Oncology Announces European Commission Authorization Of Rubraca For Women With Recurrent Ovarian Cancer
4/16/2018 9:01:27 PM Clovis Oncology Announces Upsizing And Pricing Of Offering Of $300 Mln Amount Of 1.25% Convertible Senior Notes Due 2025
4/16/2018 6:45:27 AM Clovis Intends To Offer $200 Mln Of Convertible Senior Notes Due 2025 And $100 Million Of Shares Of Common Stock
3/23/2018 8:57:55 AM Clovis Oncology Says CHMP Grants Positive Opinion For Its Rubraca Tablets
2/27/2018 8:59:50 AM RBC Capital Markets Is Lowering Clovis Oncology, Inc. (CLVS) FY18 Rev. Estimate To 122.8 M From 131.5 M
2/27/2018 8:59:37 AM RBC Capital Markets Is Cutting Clovis Oncology, Inc. (CLVS) Q1 18 Rev. Estimate To 18.1 M From 19.6 M
2/27/2018 8:59:19 AM RBC Capital Markets Is Increasing Clovis Oncology, Inc. (CLVS) FY19 Estimate To -1.64 From -2.02